Webcast ImageWebcast
Q3 2014 Laboratory Corporation of America Holdings Earnings Conference Call  (Replay)
10/28/14 at 9:00 a.m. ET
Corporate Profile

Laboratory Corporation of America® Holdings, an S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $5.8 billion in 2013, over 34,000 employees worldwide, and more than 220,000 clients, LabCorp offers more than 4,000 tests ranging from routine blood analyses to reproductive genetics to companion diagnostics. LabCorp furthers its scientific expertise and innovative clinical testing technolo... More >>

Recent NewsMore >>
10/28/14Laboratory Corporation of America® Holdings Announces 2014 Third Quarter Results and Increases 2014 EPS Guidance
Strong volume growth drives sales of $1.55 billion Diluted EPS of $1.59; Adjusted EPS of $1.80 Operating Cash Flow of $176 million; Free Cash Flow of $123 million 2014 Adjusted EPS guidance raised to $6.70 - $6.80 BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 28, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced results for the quarter ended Septemb... 
Printer Friendly Version
10/20/14LabCorp Introduces HIV-1 Next Generation Sequencing Assay to Support Drug Regimen Changes in HIV Suppressed Patients
GenoSure ArchiveSM is the first genotypic drug resistance assay to interrogate HIV-1 DNA BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 20, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) and Monogram Biosciences, Inc., part of the LabCorp Specialty Testing Group, today announced the launch of HIV GenoSure ArchiveSM, the first laboratory test to help optimize antiretroviral (ARV) drug regimens in virally suppressed HIV patien... 
Printer Friendly Version
10/15/14LabCorp’s Acquisition of LipoScience Clears Antitrust Approval
BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 15, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to the acquisition of LipoScience, Inc. (NASDAQ: LPDX) by LabCorp. Early termination of the waiting period satisfies one of the conditions necessary t... 
Printer Friendly Version
10/01/14Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 1, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and T... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
LH (Common)
Change Stock is Up 1.90
Intraday High$109.47
Intraday Low$108.24
Data as of 10/31/14
4:05 p.m. ET
Minimum 20 minute delay
Refresh quote

Reports & Performance

2013 Annual Report

2012 Annual Report

2011 Annual Report

2010 Annual Report

2009 Annual Report

2008 Annual Report

2007 Annual Report

2006 Annual Report

Latest Earnings Release